82 related articles for article (PubMed ID: 23567896)
1. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.
Wang W; He W; Wang L; Zhang G; Gao B
Immunol Cell Biol; 2013 May; 91(5):360-7. PubMed ID: 23567896
[TBL] [Abstract][Full Text] [Related]
2. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
Lei G; Xu M; Xu Z; Lu C; Tan S
Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice.
Shi J; Liu Y; Zheng Y; Guo Y; Zhang J; Cheung PT; Xu R; Zheng D
Cancer Res; 2006 Dec; 66(24):11946-53. PubMed ID: 17178893
[TBL] [Abstract][Full Text] [Related]
4. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
5. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
6. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
8. Analysis of aDR5scFv with Specific Identification and Function.
Cheng X; Meng Q; Gao C; Zhuang G; Huang X; Zhang J; Liu B; Fan X; Zhang M
Monoclon Antib Immunodiagn Immunother; 2016 Feb; 35(1):25-31. PubMed ID: 26871512
[TBL] [Abstract][Full Text] [Related]
9. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
10. [Screening of anti-human death receptor 5 antibody from a large natural phage antibody library].
Jiang X; He L; Wang Y; Ding L; Wu C; Xiong L; Zhou L; Wang Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):833-7. PubMed ID: 26062430
[TBL] [Abstract][Full Text] [Related]
11. COMBODY: one-domain antibody multimer with improved avidity.
Zhu X; Wang L; Liu R; Flutter B; Li S; Ding J; Tao H; Liu C; Sun M; Gao B
Immunol Cell Biol; 2010 Aug; 88(6):667-75. PubMed ID: 20212511
[TBL] [Abstract][Full Text] [Related]
12. Tetravalent antibody-scTRAIL fusion proteins with improved properties.
Seifert O; Plappert A; Fellermeier S; Siegemund M; Pfizenmaier K; Kontermann RE
Mol Cancer Ther; 2014 Jan; 13(1):101-11. PubMed ID: 24092811
[TBL] [Abstract][Full Text] [Related]
13. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
14. 2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.
Li M; Wu Y; Qiu Y; Yao Z; Liu S; Liu Y; Shi J; Zheng D
Mol Ther; 2012 Jan; 20(1):46-53. PubMed ID: 21934654
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
16. An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.
Siegemund M; Seifert O; Zarani M; Džinić T; De Leo V; Göttsch D; Münkel S; Hutt M; Pfizenmaier K; Kontermann RE
MAbs; 2016 Jul; 8(5):879-91. PubMed ID: 27064440
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system.
Alam MK; Brabant M; Viswas RS; Barreto K; Fonge H; Ronald Geyer C
BMC Biotechnol; 2018 Sep; 18(1):55. PubMed ID: 30200951
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.
Schneider B; Münkel S; Krippner-Heidenreich A; Grunwald I; Wels WS; Wajant H; Pfizenmaier K; Gerspach J
Cell Death Dis; 2010 Aug; 1(8):e68. PubMed ID: 21364672
[TBL] [Abstract][Full Text] [Related]
19. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.
Zheng P; Zhang Y; Zhang B; Wang Y; Wang Y; Yang L
Biomed Pharmacother; 2018 Nov; 107():1064-1073. PubMed ID: 30257318
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
